This Article Abstract Full Text (PDF) All Versions of this Article: 91/1/17    most recent 01.RES.0000025269.60668.0Fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rebsamen, M. C. Articles by Liao, J. K. Search for Related Content PubMed PubMed Citation Articles by Rebsamen, M. C. Articles by Liao, J. K. Related Collections Pathophysiology Cell signalling/signal transduction Smooth muscle proliferation and differentiation Mechanism of atherosclerosis/growth factors

(Circulation Research. 2002;91:17.)
© 2002 American Heart Association, Inc.

Molecular Medicine

1,25-Dihydroxyvitamin D₃ Induces Vascular Smooth Muscle Cell Migration via Activation of Phosphatidylinositol 3-Kinase

Michela C. Rebsamen, Jianxin Sun, Anthony W. Norman, James K. Liao

From Vascular Medicine Research (M.C.R., J.S., J.K.L.), Brigham and Women’s Hospital and Harvard Medical School, Cambridge, Mass; and the Department of Biochemistry and the Division of Biomedical Sciences (A.W.N.), University of California, Riverside, Calif.

Correspondence to James K. Liao, MD, Vascular Medicine Research, Brigham & Women’s Hospital, 65 Landsdowne St, Room 275, Cambridge, MA 02139. E-mail jliao{at}rics.bwh.harvard.edu

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
The steroid hormone 1,25-dihydroxyvitamin D₃ [1, 25-(OH)₂D₃] promotes vascular smooth muscle cell (VSMC) growth and calcification, but the precise mechanism by which 1, 25-(OH)₂D₃ regulates VSMC migration is unknown. In rat aortic SMCs, we found that 1, 25-(OH)₂D₃ (0.1 to 100 nmol/L) induced a dose-dependent increase in VSMC migration. This response required the activation of phosphatidylinositol 3-kinase (PI3 kinase) because 1, 25-(OH)₂D₃-induced migration was completely abolished by the PI3 kinase inhibitors, LY294002 (10 µmol/L) or wortmannin (30 nmol/L). Furthermore, the RNA polymerase inhibitor, 5,6-dichlorobenzimidazole riboside (50 µmol/L), did not affect 1, 25-(OH)₂D₃-induced VSMC migration, suggesting that gene transcription is not involved in this rapid response. Using analogs of 1, 25-(OH)₂D₃, which have been characterized for their abilities to induce either transcriptional or nontranscriptional responses of 1, 25-(OH)₂D₃, we found that 1,25-dihydroxylumisterol, which is a potent agonist of the rapid, nongenomic responses, was equipotent with 1, 25-(OH)₂D₃ in inducing PI3 kinase activity and VSMC migration. Moreover, 1ß, 25-(OH)₂D₃, which specifically antagonizes the nongenomic actions of 1, 25-(OH)₂D₃, abolished 1, 25-(OH)₂D₃-induced PI3 kinase activity and VSMC migration, whereas the inhibitor of the genomic actions of vitamin D, (23S)-25-dehydro-1-OH-D₃-26,23-lactone, did not affect these responses. These results indicate that 1, 25-(OH)₂D₃ induces VSMC migration independent of gene transcription via PI3 kinase pathway, and suggest a possible mechanism by which 1, 25-(OH)₂D₃ may contribute to neointima formation in atherosclerosis and vascular remodeling.

Key Words: steroid hormones • smooth muscle • migration • phosphatidylinositol 3-kinase

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
The steroid hormone, 1,25-dihydroxyvitamin D₃ [1, 25-(OH)₂D₃], elicits many physiological responses in a variety of cells¹ via the vitamin D receptor (VDR) and its cognate DNA responsive element (VDRE).² VDR belongs to the nuclear receptor superfamily for steroid hormones, retinoic acid, and thyroid hormone (T₄).³ These receptors bind to their responsive elements and alter downstream gene transcription. In addition, 1, 25-(OH)₂D₃ has also been shown to produce rapid, nongenomic (ie, VDRE-independent) responses.⁴ Indeed, 1, 25-(OH)₂D₃ stimulates a wide array of rapid responses including rapid intestinal absorption of calcium (transcaltachia),⁵ store-operated calcium influx,⁶ activation of protein kinase C, ⁷ and opening of voltage-gated calcium and chloride channels.⁸

Although the precise molecular mechanisms by which these rapid nongenomic responses are regulated remain unclear, a putative membrane receptor for 1, 25-(OH)₂D₃ or alternative pathways of the nuclear VDR have been proposed.⁹ Analogs of 1, 25-(OH)₂D₃ have been used to differentiate the genomic (ie, VDRE-dependent) versus nongenomic responses. These analogs take advantage of the flexible conformation of 1, 25-(OH)₂D₃ at the 6,7 carbon-carbon single bond (Figure 1). Rapid rotation about this bond allows generation of a continuum of various shapes of 1,25-(OH)₂D₃ ranging from the planar extended 6-s-trans conformation to the steroid-like 6-s-cis conformation^10,11; these various shapes are then available to serve as ligands for appropriate receptors. Indeed, the 6-s-cis-locked analog 1, 25-dihydroxylumisterol is a fully potent agonist of rapid, nongenomic responses of 1, 25-(OH)₂D₃.⁵ Thus, it has been proposed that different shapes of the conformationally flexible 1, 25-(OH)₂D₃ are agonists for the rapid, nongenomic (6-s-cis) and genomic (twisted 6-s-trans) responses.¹² In addition, analogs that antagonize 1, 25-(OH)₂D₃ responses have also been characterized. Indeed, 1ß, 25-(OH)₂D₃ (HL) is a specific antagonist of nongenomic action of 1, 25-(OH)₂D₃,^8,13 whereas (23S)-25-dehydro-1-OH-D₃-26,23-lactone (MK) preferentially inhibits genomic responses.¹⁴

View larger version (21K): [in this window] [in a new window]   Figure 1. Structure of the steroid hormone 1, 25-(OH)2D3 and related analogs. 1, 25-(OH)2D3 has 360° rotational flexibility around the 6,7 single carbon bond; the two extreme conformers, the steroid-like 6-s-cis and the extended 6-s-trans are shown. This 360° rotation around the 6,7 carbon bond, which is a reflection of the chemical properties of the single carbon bond, occurs millions of times per second and generates a continuum of shapes that are available for ligand binding to any vitamin D-related receptor(s) that may be present. Thus, the conformationally flexible 1, 25-(OH)2D3 is able to generate shapes that satisfy the receptor requirements both for genomic responses (VDR) as well as rapid nongenomic responses.5 In contrast, the analog 1,25-(OH)2-lumisterol (JN) has a 9,10 carbon bond that locks it exclusively in the 6-s-cis shape with the consequence that it is a full agonist only for rapid nongenomic responses, but is not an agonist for genomic responses.5 The analog 1ß, 25-(OH)2D3 (HL) is an antagonist for only rapid nongenomic responses.13 The compound (23S)-25-dehydro-1-OH-D3-26,23-lactone (MK) is an antagonist of only genomic responses.14

Recent studies suggest that 1, 25-(OH)₂D₃ plays an important role in the cardiovascular system through its receptors in the heart and in vascular smooth muscle cells (VSMCs).^15,16 In particular, 1,25-(OH)₂D₃ has been shown to regulate calcium homeostasis, modulate growth, and increase calcification in smooth muscle cells.^17–19 Indeed, the mitogenic role of 1, 25-(OH)₂D₃ in VSMCs has been previously reported,^18,20,21 although its effect on the migration has not been investigated. Therefore, the purpose of this study was to determine whether 1, 25-(OH)₂D₃ can promote SMC migration, and if so, to determine whether the mechanism is mediated by the genomic or nongenomic effects of VDR.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Materials
1, 25-(OH)₂D₃ was purchased from Biomol Research Laboratories Inc. 1, 25-(OH)₂-lumisterol (JN), 1ß, 25-(OH)₂D₃ (HL), and (23S)-25-dehydro-1-OH-D₃-26,23-lactone (MK) were generously provided by A.W. Norman and W.H. Okamura (University of California, Riverside, Calif).

Cell Culture
Rat aortic VSMCs were harvested from Sprague-Dawley rats (Taconic Farms, Germantown, NY) by enzymatic dissociation according to the method of Gunther et al.²² Cells were grown in Dulbecco’s modified Eagle’s medium (Life Technologies, Inc) supplemented with 10% fetal calf serum (Hyclone), penicillin (100 U/mL), streptomycin (100 U/mL), and fungizone (1.25 µg/mL). Cellular viability under the experimental conditions was determined by cell number, cellular morphology, and trypan blue exclusion. The guidelines on handling and care of animals were approved by our institutional Animal Care Committee.

Migration Assay
VSMC migration was examined in modified Boyden transwell cell culture chambers using a gelatin-treated polycarbonate membrane with 8-µm pores in 24-well plates (Costar Inc). Cells were grown to 80% confluence and starved for 48 hours in DMEM containing 0.4% charcoal-stripped FCS. After starvation cells were trypsinized, counted, and resuspended in serum-free DMEM to a concentration of 2x10⁵ cells/mL. Cells (100 µL) were then added to the upper chamber, while the lower chamber was filled with 600 µL of DMEM containing the appropriate concentration of agonist or vehicle. After 4 hours incubation at 37°C, cells were removed from the upper side of the membranes with cotton swabs. The membranes were then fixed with methanol (10 minutes at 4°C) and stained with hematoxylin. The number of migrated cells was counted under microscope (magnification, 400x). Three randomly chosen fields were counted per membrane, and each experiment was performed in triplicate.

Adhesion Assay
VSMC adhesion was assessed in transwell cell culture chambers after a procedure similar to that described above for the migration assay. Briefly, cells were resuspended to a concentration of 2x10⁴ cells/mL, and 2x10³ cells were added to the upper chamber. DMEM containing the appropriate concentration of agonist or vehicle was added to the lower chamber. After 2 hours incubation at 37°C in a 5% CO₂ incubator, the media containing nonadherent cells was removed, and cells fixed on the upper surface of the membranes were counted. Experiments were performed in triplicate.

Phosphatidylinositol 3-Kinase Assay
Phosphatidylinositol 3-kinase (PI3 kinase) activity in VSMC lysates was assayed using the borate thin layer chromatography method as described.²³ After the indicated treatment conditions in DMEM containing 0.4% charcoal-stripped FCS, cells were harvested in ice-cold lysis buffer (in mmol/L: 137 NaCl, 20 Tris-HCl [pH 7.4], 1 CaCl₂, 1 MgCl₂, 0.1 Na₃VO₄, 1% NP-40). After pelleting the cell debris, the supernatant was incubated for 1 hour at 4°C with 5 µL of a VDR antibody (recognizes C-terminus, ligand-binding domain, 1 µg; Santa Cruz Biotechnology) and immunoprecipitated with the addition of 50 µL of a 1:1 slurry of protein A-agarose for 1 hour at 4°C. After centrifugation, the immunoprecipitates were washed 3 times with lysis buffer, 3 times with 0.1 mol/L Tris-HCl, pH 7.4, 5 mmol/L LiCl, and 0.1 mmol/L Na₃VO₄, followed by 2 washes with (in mmol/L) 10 Tris-HCl (pH 7.40), 150 NaCl, 5 EDTA, and 0.1 Na₃VO₄.

The immunoprecipitates were then mixed with 50 µL Tris-HCl (pH 7.4), 150 mmol/L NaCl, 5 mmol/L EDTA, 20 µg of phosphatidylinositol-3,4-bisphosphate (PIP₂, Sigma), 10 µL 100 mmol/L MgCl₂, and 5 µL of a 0.88 mmol/L ATP, 20 mmol/L MgCl₂ solution, containing 30 µCi of [-³²P]ATP (3000 Ci/mmol; NEN Life Science Products). The reaction was incubated at 37°C for 10 minutes, and subsequently blocked by the addition of 20 µL of 6N HCl. The phospholipids were extracted with 160 µL of chloroform/methanol (1:1, v/v). The organic phase (50 µL), containing the labeled PI3 kinase products, was separated by borate thin layer chromatography on glass-backed Silica Gel 60 plates (EM Separations) pretreated with a solution containing 25 mmol/L trans-1,2-diaminocyclohexane-N,N,N'N'-tetraacetic acid (CDTA, Sigma), 66% (v/v) ethanol, and 0.06 N NaOH, dried for 1 hour and then baked at 100°C for 15 minutes. The chromatography was developed with a solution containing 37.5% (v/v) methanol, 30% (v/v) chloroform, 22.5% (v/v) pyridine (Sigma), 1.33% (v/v) formic acid, 1 mol/L boric acid and 8.5 mmol/L butylated hydroxytoluene (Sigma), briefly dried, and exposed to autoradiography.

Western Blotting
After 24 hours stimulation in DMEM containing 0.4% charcoal-stripped FCS, VSMCs were washed with ice-cold PBS and lysed with 500 µL of the following buffer: Tris-HCl (20 mmol/L, pH 7.4), EDTA (10 mmol/L), NaCl (100 mmol/L), IGEPAL (1%), Na₃VO₄ (1 mmol/L), NaF (50 mmol/L) containing a cocktail of protease inhibitors (Roche). Proteins (20 µg) were separated by SDS-PAGE on a 10% acrylamide gel and blotted onto nitrocellulose membrane (Osmonics). Afterward, membranes were incubated for 2 hours at room temperature with antibodies raised against osteopontin (Santa Cruz Biotech.) or -tubulin (DM1A, Sigma). Then, the blots were washed and incubated for 1 hour with horseradish peroxidase-labeled anti-goat (Santa Cruz Biotech.) or anti-mouse (Amersham Phamacia) antibodies, respectively. Immunoreactive bands were visualized with a chemiluminescence kit (PerkinElmer Life Science) and quantified by densitometry.

Statistical Analysis
All values are expressed as mean±SEM. Differences between groups were determined by the unpaired, 2-tailed Student’s t test. Values of P<0.05 were accepted as statistically significant.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cell Culture
Relatively pure (>95%) rat aortic SMCs were confirmed by their morphological features using phase-contrast microscopy and immunofluorescent staining with a smooth muscle-specific MHC antibody (data not shown). There were no observable adverse effects of wortmannin, LY294002, or 5,6-dichlorobenzimidazole riboside (DRB) on cellular viability for all experimental conditions, except when given for >12 hours (ie, trypan blue exclusion is 85% to 90% versus >95% for <12 hours).

PI3 Kinase Mediates 1,25-Dihydroxyvitamin D₃-Induced VSMC Migration
The effect of 1,25-dihydroxyvitamin D₃ on VSMC migration was assessed using a modified Boyden transwell cell culture chamber. The addition of 1,25-(OH)₂D₃ in the lower compartment of the transwells induced a concentration-dependent increase of VSMC migration. Indeed, physiological 1, 25-(OH)₂D₃ concentrations ranging from 0.1 to 100 nmol/L increased VSMC migration by 19% to 42% over control (P<0.05, n=3; Figure 2A). Because migration is, in part, dependent on the adhesion of the VSMCs to the transwell membrane, we tested whether 1, 25-(OH)₂D₃ had any effect on VSMC adhesion. As shown in Figure 2B, the number of cells attached to the upper side of the transwell membrane was not affected by 1, 25-(OH)₂D₃.

View larger version (14K): [in this window] [in a new window]   Figure 2. 1,25-dihydroxyvitamin D3 induces VSMC migration. A, Effect of increasing concentrations of 1,25-(OH)2D3 (1,25D3) on VSMC migration. Experiments were performed 3 times in triplicates. *P<0.05 compared with unstimulated cells. B, Effect of 1, 25-(OH)2D3 (100 nmol/L) on VSMC adhesion. Results are expressed as number of cells per field (magnification, 400x). Experiments were performed twice in triplicates.

A role for PI3 kinase in VSMC migration has been previously reported.^24,25 Therefore, we investigated whether 1, 25-(OH)₂D₃-induced VSMC migration was dependent on PI3 kinase activity. Studies were performed using two selective inhibitors of PI3 kinase: wortmannin and LY294002. Preincubation of VSMCs for 30 minutes with wortmannin (30 nmol/L) or LY294002 (10 µmol/L), which selectively inhibits PI3 kinase, abolished the VSMC migration induced by 10 nmol/L of 1, 25-(OH)₂D₃ (P<0.05, n=3) (Figure 3). These results suggest that 1, 25-(OH)₂D₃ increases the migration of VSMCs and that this response requires the activation of PI3 kinase.

View larger version (12K): [in this window] [in a new window]   Figure 3. VSMC migration induced by nontranscriptional activation of PI3 kinase by 1,25-dihydroxyvitamin D3. VSMC migration was induced by 10 nmol/L of 1, 25-(OH)2D3. PI3 kinase was inhibited preincubating cells for 30 minutes with LY294002 (LY, 10 µmol/L) or wortmannin (Wort, 30 nmol/L). To inhibit gene transcription, cells were preincubated for 30 minutes with 5,6-dichlorobenzimidazole riboside (DRB, 50 µmol/L). Experiments were performed 3 times in triplicates. *P<0.05 compared with unstimulated cells.

Activation of PI3 Kinase by 1, 25-(OH)₂D₃ in VSMCs
To further support the hypothesis that PI3 kinase is involved in 1, 25-(OH)₂D₃-induced VSMC migration, we tested whether 1, 25-(OH)₂D₃ can induce PI3 kinase activity. As shown in Figure 4A, stimulation of VSMCs with 1, 25-(OH)₂D₃ (10 nmol/L) induced a rapid time-dependent increase in VDR-associated PI3 kinase activity. Indeed, after 10 and 30 minutes, 1, 25-(OH)₂D₃ (1 nmol/L) increased PI3 kinase activity by 5- and 10-fold, respectively. In agreement with the results obtained in our migration assays, the dose-response experiments revealed an increase in PI3 kinase activity using 1,25-(OH)₂D₃ concentrations as low as 0.1 nmol/L (P<0.05, n=3; Figure 4B). The 1, 25-(OH)₂D₃-induced PI3 kinase activity was abolished in cells pretreated for 30 minutes with wortmannin or LY294002 (Figure 4C).

View larger version (29K): [in this window] [in a new window]   Figure 4. 1,25-dihydroxyvitamin D3 induces PI3 kinase activity in VSMCs. A, Time-dependent (5 to 60 minutes) increase in PI3 kinase activity induced by 1, 25-(OH)2D3 (1 nmol/L) compared with unstimulated or control cells (C). B, Effect of increasing concentrations of 1, 25-(OH)2D3 on PI3 kinase activity. Cells were stimulated for 10 minutes with 1, 25-(OH)2D3 (0.01 to 10 nmol/L) or left untreated (C). C, Effect of wortmannin (Wort, 30 nmol/L), LY294002 (LY, 10 µmol/L), or DRB (50 µmol/L) on PI3 kinase activity induced by 1, 25-(OH)2D3 (10 nmol/L). All experiments were performed 3 times with comparable results.

Nontranscriptional Effect of 1, 25-(OH)₂D₃ on VSMC Migration
1, 25-(OH)₂D₃ has been shown to generate biological responses via both genomic and rapid nongenomic pathways.^1,26–28 To determine whether 1, 25-(OH)₂D₃-induced migration involves gene transcription, VSMCs were treated for 30 minutes with the RNA polymerase inhibitor, 5,6-dichlorobenzimidazole riboside (DRB, 50 µmol/L) before 1, 25-(OH)₂D₃ stimulation. DRB did not affect 1, 25-(OH)₂D₃-induced VSMC migration or PI3 kinase activity, suggesting that gene transcription is not involved in these responses (Figures 3 and 4C). Indeed, treatment of VSMCs with DRB inhibited TNF--induced gene transcription by >95% using nuclear run-on analyses (data not shown).

VSMC Migration Mediated by Stereospecific Activation of VDR
The 6-s-cis-locked, 1,25-dihydroxyvitamin D₃ analog, 1, 25-(OH)₂-lumisterol₃ (JN), has been shown to be the most effective agonist of the rapid nongenomic responses characteristic of 1,25-dihydroxyvitamin D₃.⁵ Therefore, we used this analog to further study the hypothesis that the migration of VSMCs induced by 1,25-dihydroxyvitamin D₃ is a nongenomic response. Similarly to 1,25-(OH)₂D₃, 1 and 10 nmol/L of JN significantly increased VSMC migration by 28% and 41%, respectively (P<0.05, n=3; Figure 5A). Moreover, the same analog induced a rapid, dose-dependent increase in PI3 kinase activity (Figures 5B and 5C). Indeed, after 10 minutes stimulation with 1 and 10 nmol/L of JN, PI3 kinase activity was increased approximately by 4.5- and 11-fold, respectively. To verify that JN does not induce VDRE-dependent responses in VSMCs, we measured the expression of osteopontin, a protein induced by 1, 25-(OH)₂D₃ in SMCs.^1,29 Stimulation with 1, 25-(OH)₂D₃ increased the amount of osteopontin protein in VSMCs by approximately 2-fold (P<0.05, n=3), which was completely blocked by cotreatment with the transcriptional inhibitor, DRB (50 µmol/L; Figure 6). Consistent with its established nongenomic action, JN did not affect osteopontin expression in VSMCs. Our results indicate that the JN analog is equipotent with 1, 25-(OH)₂D₃ in inducing PI3 kinase activation and migration in VSMCs and support the hypothesis that gene transcription is not involved in these responses.

View larger version (20K): [in this window] [in a new window]   Figure 5. 1,25-(OH)2-lumisterol (JN) induces VSMC migration and PI3 kinase activity. A, Effect of JN (1 and 10 nmol/L) on VSMC migration. Experiments were performed 3 times in triplicates. *P<0.05 compared with unstimulated cells. B, Time-dependent (10 to 30 minutes) increase in PI3 kinase activity induced by JN (1 nmol/L) compared with unstimulated cells (C). C, Effect of increasing concentrations of JN on PI3 kinase activity. Cells were stimulated for 10 minutes with JN (1 to 100 nmol/L) or left untreated (C). Experiments were performed 3 times with comparable results.

View larger version (31K): [in this window] [in a new window]   Figure 6. Effect of 1,25-dihydroxyvitamin D3 and JN on osteopontin expression in VSMCs. A, Cells were stimulated for 24 hours with 1, 25-(OH)2D3 (1 nmol/L), JN (1 nmol/L), or left untreated (Control) in the presence or absence of DRB (50 µmol/L). Osteopontin (OPN) protein level was detected by Western blotting and equivalent loading was standardized to that of -tubulin. B, Immunoreactive bands corresponding to OPN were quantitated by densitometric analysis. Blots are representative of results obtained in three separate experiments. *P<0.05 compared with unstimulated cells (Control).

We next tested two specific antagonists of the VDR. 1ß,25-(OH)₂D₃ (HL) has been shown to be a potent antagonist of rapid responses,¹³ whereas (23S)-25-dehydro-1-OH-D₃-26,23-lactone (antagonist MK) preferentially antagonizes nuclear responses.¹⁴ Therefore, we studied the effects of these two antagonists on 1, 25-(OH)₂D₃-induced VSMC migration. We found that HL, but not MK, inhibited VSMC migration induced by 1, 25-(OH)₂D₃ (Figure 7A). Consistent with these results, MK did not significantly affect 1, 25-(OH)₂D₃-induced PI3 kinase activity, although HL almost completely inhibited this response (Figure 7B). Taken together, our data suggest that 1, 25-(OH)₂D₃ induces VSMC migration through the nontranscriptional activation of PI3 kinase.

View larger version (16K): [in this window] [in a new window]   Figure 7. Effect of 1ß, 25-(OH)2D3 (HL) and (23S)-25-dehydro-1-OH-D3-26,23-lactone (MK) on 1, 25-(OH)2D3-induced VSMC migration and PI3 kinase activity. A, VSMC migration was induced by 1 nmol/L of 1, 25-(OH)2D3 in the presence or in the absence of 50 nmol/L of HL or MK. Experiments were performed 3 times in triplicates. *P<0.05 compared with unstimulated cells (Control). B, Effect of HL or MK (50 nmol/L) on PI3 kinase activity induced by 1, 25-(OH)2D3 (1 nmol/L). Experiments were performed 3 times with comparable results.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
In the present study, we showed that 1, 25-(OH)₂D₃ induced a dose-dependent increase in VSMC migration with significant responses observed above 0.1 nmol/L. This concentration is comparable with the physiological level of total circulating 1, 25-(OH)₂D₃.³⁰ Furthermore, much higher local concentrations of 1, 25-(OH)₂D₃ could be reached under pathophysiological conditions. Indeed, monocytes and macrophages have been shown to produce 1, 25-(OH)₂D₃ in a paracrine manner after stimulation with inflammatory stimuli.^31–33 Our observation that 1, 25-(OH)₂D₃–induced VSMC migration requires PI3 kinase activation is in agreement with the role of PI3 kinase in cell migration processes regulated by cytokines and growth factors in diverse cell types including VSMCs.^34–36 We found an induction of VDR-associated PI3 kinase activity by 1, 25-(OH)₂D₃ in VSMCs. This observation is consistent with that reported by Hmama et al³⁷ in myeloid cells.

Our findings further indicated that the VSMC migration induced by 1, 25-(OH)₂D₃ was a rapid response that is independent of VDRE-regulated gene transcription. For instance, the RNA polymerase inhibitor DRB did not affect 1, 25-(OH)₂D₃-induced VSMC migration and 1, 25-(OH)₂D₃ rapidly induced (ie, within 10 minutes) PI3 kinase activity that correlated with VSMC migration. Furthermore, we found that the 1, 25-(OH)₂D₃ 6-s-cis-locked analog JN, which has been reported to specifically induce the nongenomic responses characteristic of 1, 25-(OH)₂D₃ in several cell types,^5,38 mimicked both 1, 25-(OH)₂D₃-induced PI3 kinase activation and VSMC migration. Finally, the 1, 25-(OH)₂D₃ antagonist HL, which specifically blocks the nongenomic responses of 1, 25-(OH)₂D₃,^8,13,38 inhibited both 1, 25-(OH)₂D₃-induced PI3 kinase activation and VSMC migration. These findings suggest that there may exist a rapid-response membrane receptor that mediates the nongenomic actions of 1, 25-(OH)₂D₃. However, because the cis to trans configuration of 1, 25-(OH)₂D₃ occurs fairly rapidly and has not been shown to be affected under pathophysiological conditions, it is unlikely that changes in the ratio of cis to trans isoform contribute to the diversity of SMC response to 1, 25-(OH)₂D₃. Rather it is probably due to the "dual" ligand nature of 1, 25-(OH)₂D₃ and the phenotypic state of SMC, with the cis isoform eliciting SMC migration via the PI3 kinase pathway.

The mechanism underlying this nongenomic response is not completely understood. Our PI3 kinase assays indicate that a signaling complex containing both the VDR and PI3 kinase is formed after 1,25-(OH)₂D₃ stimulation. The identity and characterization of the VDR involved in this nongenomic response remains to be determined. However, the antibody used in our assay recognizes the C-terminal region of the nuclear VDR, suggesting that the classical nuclear VDR mediates PI3 kinase activation rather than a novel membrane receptor. A similar observation was reported concerning the nongenomic effects of estrogen in endothelial cells.³⁹ Indeed, the estrogen receptor was shown to induce PI3 kinase activation by binding to the PI3 kinase regulatory subunit p85. Also Kousteni et al⁴⁰ have described nontraditional results for both the estrogen and androgen nuclear receptors in osteoblasts, where they are shown to be involved in activation of a Src/Shc/ERK signaling pathway and rapid attenuation of apoptosis. These actions were mediated by nuclear receptors, under circumstances that eliminated nuclear targeting of the receptor proteins. Further, they demonstrated that the antiapoptotic rapid action could be dissociated from the transcriptional activity of the receptors by use of synthetic ligands that are specific for either genomic or rapid actions. This is analogous to our use of 6-s-cis-locked analogs of 1, 25-(OH)₂D₃.

The present results also demonstrate that the 6-s-cis-locked analog JN is a potent agonist of the signaling nuclear VDR/PI3 kinase complex and implies that the nuclear VDR can productively interact with this ligand. However, this conclusion is at variance with the weak affinity of JN for the nuclear VDR in a simple in vitro binding study (<0.5%)⁵ or in settings where the nuclear VDR (occupied by JN) is interacting with VDRE to initiate classic genomic responses (<1.5%),⁵ both in comparison to 1, 25-(OH)₂D₃. Thus, the present PI3 kinase system affords an unusual opportunity to decipher and understand the how the nuclear VDR in the presence of 6-s-cis-shaped analogs mediates productive biological responses. Interestingly, Baran et al have recently shown that annexin II can bind 1, 25-(OH)₂D₃ as a membrane receptor and mediate the rapid responses of 1, 25-(OH)₂D₃ on calcium influx.^41,42 Although we have shown that VDR can associate with PI3 kinase in a ligand-dependent manner, similar findings have not been reported for annexin II. Thus, it is possible that VDR and annexin can both function as membrane receptors, which mediate distinct, nongenomic actions of 1, 25-(OH)₂D₃.

A possible downstream target of PI3 kinase in 1, 25-(OH)₂D₃-induced VSMC migration is the focal adhesion kinase (FAK), which is a cytoplasmic tyrosine kinase that plays a crucial role in the migration process.⁴³ Because PI3 kinase activity has been shown to be required for PDGF-induced FAK phosphorylation,⁴⁴ it is possible that a similar pathway is activated by 1, 25-(OH)₂D₃. On the other hand, Src kinases have also been shown to induce FAK phosphorylation and, therefore, play a role in cell migration.⁴⁵ In this context, the nuclear VDR has also been shown to activate tyrosine phosphorylation pathways.^46,47 In particular, 1, 25-(OH)₂D₃ has been reported to induce Src activation and association to tyrosine phosphorylated VDR.⁴⁸ As it has recently been shown for the estrogen receptor (ER),⁴⁹ it is possible that a complex consisting of VDR, Src, and PI3 kinase may form after 1, 25-(OH)₂D₃ stimulation, mediate the subsequent phosphorylation of FAK, and increase cell migration. However, the subcellular distribution of ER differs from VDR, and therefore, the mechanism by which VDR activates PI3 kinase may be very different from that of ER. Future studies aimed to elucidate the potential role of Src and FAK in 1, 25-(OH)₂D₃-induced VSMC migration will help identify the possible interaction between these proteins and the VDR response in the vascular wall.

	Acknowledgments

 
This work was supported by the National Institutes of Health grants HL70274, HL52233, HL48743, and DK09012. M.C.R. is a recipient of the Swiss National Science Foundation Fellowship.

Received December 19, 2001; revision received May 8, 2002; accepted May 28, 2002.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 
1. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998; 78: 1193–1231.[Abstract/Free Full Text]

2. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998; 13: 325–349.[CrossRef][Medline] [Order article via Infotrieve]

3. Weatherman RV, Fletterick RJ, Scanlan TS. Nuclear-receptor ligands and ligand-binding domains. Annu Rev Biochem. 1999; 68: 559–581.[CrossRef][Medline] [Order article via Infotrieve]

4. Norman AW, Nemere I, Zhou LX, Bishop JE, Lowe KE, Maiyar AC, Collins ED, Taoka T, Sergeev I, Farach-Carson MC. 1,25(OH)₂-vitamin D₃, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways. J Steroid Biochem Mol Biol. 1992; 41: 231–240.[CrossRef][Medline] [Order article via Infotrieve]

5. Norman AW, Okamura WH, Hammond MW, Bishop JE, Dormanen MC, Bouillon R, van Baelen H, Ridall AL, Daane E, Khoury R, Farach-Carson MC. Comparison of 6-s-cis- and 6-s-trans-locked analogs of 1,25- dihydroxyvitamin D₃ indicates that the 6-s-cis conformation is preferred for rapid nongenomic biological responses and that neither 6-s-cis- nor 6-s-trans-locked analogs are preferred for genomic biological responses. Mol Endocrinol. 1997; 11: 1518–1531.[Abstract/Free Full Text]

6. Vazquez G, de Boland AR, Boland RL. 1,25-dihydroxy-vitamin-D₃-induced store-operated Ca²⁺ influx in skeletal muscle cells: modulation by phospholipase c, protein kinase c, and tyrosine kinases. J Biol Chem. 1998; 273: 33954–33960.[Abstract/Free Full Text]

7. Bissonnette M, Wali RK, Hartmann SC, Niedziela SM, Roy HK, Tien XY, Sitrin MD, Brasitus TA. 1,25-Dihydroxyvitamin D₃ and 12-O-tetradecanoyl phorbol 13-acetate cause differential activation of Ca²⁺-dependent and Ca²⁺-independent isoforms of protein kinase C in rat colonocytes. J Clin Invest. 1995; 95: 2215–2221.[CrossRef][Medline] [Order article via Infotrieve]

8. Zanello LP, Norman AW. Stimulation by 1,25(OH)₂-vitamin D₃ of whole cell chloride currents in osteoblastic ROS 17/2.8 cells: a structure-function study. J Biol Chem. 1997; 272: 22617–22622.[Abstract/Free Full Text]

9. Nemere I, Dormanen MC, Hammond MW, Okamura WH, Norman AW. Identification of a specific binding protein for 1,25-dihydroxyvitamin D₃ in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J Biol Chem. 1994; 269: 23750–23756.[Abstract/Free Full Text]

10. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev. 1995; 16: 200–257.[Abstract/Free Full Text]

11. Okamura WH, Midland MM, Hammond MW, Abd Rahman N, Dormanen MC, Nemere I, Norman AW. Chemistry and conformation of vitamin D molecules. J Steroid Biochem Mol Biol. 1995; 53: 603–613.[CrossRef][Medline] [Order article via Infotrieve]

12. Norman AW, Henry HL, Bishop JE, Song XD, Bula C, Okamura WH. Different shapes of the steroid hormone 1,25(OH)₂-vitamin D₃ act as agonists for two different receptors in the vitamin D endocrine system to mediate genomic and rapid responses. Steroids. 2001; 66: 147–158.[CrossRef][Medline] [Order article via Infotrieve]

13. Norman AW, Bouillon R, Farach-Carson MC, Bishop JE, Zhou LX, Nemere I, Zhao J, Muralidharan KR, Okamura WH. Demonstration that 1ß,25-dihydroxyvitamin D3 is an antagonist of the nongenomic but not genomic biological responses and biological profile of the three A-ring diastereomers of 1,25-dihydroxyvitamin D₃. J Biol Chem. 1993; 268: 20022–20030.[Abstract/Free Full Text]

14. Bula CM, Bishop JE, Ishizuka S, Norman AW. 25-Dehydro-1-hydroxyvitamin D₃-26,23S-lactone antagonizes the nuclear vitamin D receptor by mediating a unique noncovalent conformational change. Mol Endocrinol. 2000; 14: 1788–1796.[Abstract/Free Full Text]

15. Walters MR, Wicker DC, Riggle PC. 1,25-Dihydroxyvitamin D₃ receptors identified in the rat heart. J Mol Cell Cardiol. 1986; 18: 67–72.[Medline] [Order article via Infotrieve]

16. Merke J, Hofmann W, Goldschmidt D, Ritz E. Demonstration of 1,25(OH)₂ vitamin D₃ receptors and actions in vascular smooth muscle cells in vitro. Calcif Tissue Int. 1987; 41: 112–114.[Medline] [Order article via Infotrieve]

17. Inoue T, Kawashima H. 1,25-Dihydroxyvitamin D₃ stimulates 45Ca²⁺-uptake by cultured vascular smooth muscle cells derived from rat aorta. Biochem Biophys Res Commun. 1988; 152: 1388–1394.[CrossRef][Medline] [Order article via Infotrieve]

18. Mitsuhashi T, Morris RC Jr, Ives HE. 1,25-dihydroxyvitamin D₃ modulates growth of vascular smooth muscle cells. J Clin Invest. 1991; 87: 1889–1895.[Medline] [Order article via Infotrieve]

19. Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-Dihydroxyvitamin D₃ increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation. 1998; 98: 1302–1306.[Abstract/Free Full Text]

20. Koh E, Morimoto S, Nabata T, Takamoto S, Kitano S, Ogihara T. Effects of 1,25-dihydroxyvitamin D₃ on the syntheses of DNA and glycosaminoglycans by rat aortic smooth muscle cells in vitro. Life Sci. 1990; 46: 1545–1551.[CrossRef][Medline] [Order article via Infotrieve]

21. Tukaj C, Kubasik-Juraniec J, Kraszpulski M. Morphological changes of aortal smooth muscle cells exposed to calcitriol in culture. Med Sci Monit. 2000; 6: 668–674.[Medline] [Order article via Infotrieve]

22. Gunther S, Alexander RW, Atkinson WJ, Gimbrone MA Jr. Functional angiotensin II receptors in cultured vascular smooth muscle cells. J Cell Biol. 1982; 92: 289–298.[Abstract/Free Full Text]

23. Walsh JP, Caldwell KK, Majerus PW. Formation of phosphatidylinositol 3-phosphate by isomerization from phosphatidylinositol 4-phosphate. Proc Natl Acad Sci U S A. 1991; 88: 9184–9187.[Abstract/Free Full Text]

24. Duan C, Bauchat JR, Hsieh T. Phosphatidylinositol 3-kinase is required for insulin-like growth factor-I-induced vascular smooth muscle cell proliferation and migration. Circ Res. 2000; 86: 15–23.[Abstract/Free Full Text]

25. Yamboliev IA, Chen J, Gerthoffer WT. PI3-kinases and Src kinases regulate spreading and migration of cultured VSMCs. Am J Physiol Cell Physiol. 2001; 281: C709–C718.[Abstract/Free Full Text]

26. Sergeev IN, Rhoten WB. 1,25-Dihydroxyvitamin D₃ evokes oscillations of intracellular calcium in a pancreatic ß-cell line. Endocrinology. 1995; 136: 2852–2861.[Abstract]

27. Beno DW, Brady LM, Bissonnette M, Davis BH. Protein kinase C and mitogen-activated protein kinase are required for 1,25-dihydroxyvitamin D₃-stimulated Egr induction. J Biol Chem. 1995; 270: 3642–3647.[Abstract/Free Full Text]

28. Bhatia M, Kirkland JB, Meckling-Gill KA. Monocytic differentiation of acute promyelocytic leukemia cells in response to 1,25-dihydroxyvitamin D₃ is independent of nuclear receptor binding. J Biol Chem. 1995; 270: 15962–15965.[Abstract/Free Full Text]

29. Chaulet H, Desgranges C, Renault MA, Dupuch F, Ezan G, Peiretti F, Loirand G, Pacaud P, Gadeau AP. Extracellular nucleotides induce arterial smooth muscle cell migration via osteopontin. Circ Res. 2001; 89: 772–778.[Abstract/Free Full Text]

30. Bikle DD, Gee E, Halloran B, Haddad JG. Free 1,25-dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and subjects with liver disease. J Clin Invest. 1984; 74: 1966–1971.[CrossRef][Medline] [Order article via Infotrieve]

31. Koeffler HP, Reichel H, Bishop JE, Norman AW. -Interferon stimulates production of 1,25-dihydroxyvitamin D₃ by normal human macrophages. Biochem Biophys Res Commun. 1985; 127: 596–603.[CrossRef][Medline] [Order article via Infotrieve]

32. Reichel H, Koeffler HP, Barbers R, Norman AW. Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. J Clin Endocrinol Metab. 1987; 65: 1201–1209.[Abstract/Free Full Text]

33. Gyetko MR, Hsu CH, Wilkinson CC, Patel S, Young E. Monocyte 1-hydroxylase regulation: induction by inflammatory cytokines and suppression by dexamethasone and uremia toxin. J Leukoc Biol. 1993; 54: 17–22.[Abstract]

34. Reiske HR, Kao SC, Cary LA, Guan JL, Lai JF, Chen HC. Requirement of phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration. J Biol Chem. 1999; 274: 12361–12366.[Abstract/Free Full Text]

35. Vanhaesebroeck B, Jones GE, Allen WE, Zicha D, Hooshmand-Rad R, Sawyer C, Wells C, Waterfield MD, Ridley AJ. Distinct PI (3)Ks mediate mitogenic signalling and cell migration in macrophages. Nat Cell Biol. 1999; 1: 69–71.[CrossRef][Medline] [Order article via Infotrieve]

36. Imai Y, Clemmons DR. Roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration and deoxyribonucleic acid synthesis by insulin-like growth factor-I. Endocrinology. 1999; 140: 4228–4235.[Abstract/Free Full Text]

37. Hmama Z, Nandan D, Sly L, Knutson KL, Herrera-Velit P, Reiner NE. 1,25-dihydroxyvitamin D₃-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. J Exp Med. 1999; 190: 1583–1594.[Abstract/Free Full Text]

38. Shi H, Norman AW, Okamura WH, Sen A, Zemel MB. 1,25-Dihydroxyvitamin D₃ modulates human adipocyte metabolism via nongenomic action. FASEB J. 2001; 2751–2753.

39. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000; 407: 538–541.[CrossRef][Medline] [Order article via Infotrieve]

40. Kousteni S, Bellido T, Plotkin LI, O’Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PI, Weinstein RS, Jilka RL, and Manolagas, SC. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001; 104: 719–730.[Medline] [Order article via Infotrieve]

41. Baran DT, Quail JM, Ray R, Leszyk J, Honeyman T. Annexin II is the membrane receptor that mediates the rapid actions of 1,25-dihydroxyvitaminD₃. J Cell Biochem. 2000; 78: 34–46.[CrossRef][Medline] [Order article via Infotrieve]

42. Baran DT, Quail JM, Ray R, Honeyman T. Binding of 1,25-dihydroxyvitamin D₃ to annexin II: effect of vitamin D metabolites and calcium. J Cell Biochem. 2000; 80: 259–265.[CrossRef][Medline] [Order article via Infotrieve]

43. Ilic D, Damsky CH, Yamamoto T. Focal adhesion kinase: at the crossroads of signal transduction. J Cell Sci. 1997; 110: 401–407.[Abstract]

44. Saito Y, Mori S, Yokote K, Kanzaki T, Morisaki N. Phosphatidylinositol 3-kinase activity is required for the activation process of focal adhesion kinase by platelet-derived growth factor. Biochem Biophys Res Commun. 1996; 224: 23–26.[CrossRef][Medline] [Order article via Infotrieve]

45. Schlaepfer DD, Hanks SK, Hunter T, van der Geer P. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature. 1994; 372: 786–791.[Medline] [Order article via Infotrieve]

46. Khare S, Bolt MJ, Wali RK, Skarosi SF, Roy HK, Niedziela S, Scaglione-Sewell B, Aquino B, Abraham C, Sitrin MD, Brasitus TA, Bissonnette M. 1,25 dihydroxyvitamin D₃ stimulates phospholipase C- in rat colonocytes: role of c-Src in PLC- activation. J Clin Invest. 1997; 99: 1831–1841.[Medline] [Order article via Infotrieve]

47. Morelli S, Buitrago C, Vazquez G, De Boland AR, Boland R. Involvement of tyrosine kinase activity in 1,25(OH)₂-vitamin D₃ signal transduction in skeletal muscle cells. J Biol Chem. 2000; 275: 36021–36028.[Abstract/Free Full Text]

48. Buitrago C, Vazquez G, De Boland AR, Boland RL. Activation of Src kinase in skeletal muscle cells by 1,25-(OH)₂-vitamin D₃ correlates with tyrosine phosphorylation of the vitamin D receptor (VDR) and VDR-Src interaction. J Cell Biochem. 2000; 79: 274–281.[CrossRef][Medline] [Order article via Infotrieve]

49. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 2001; 20: 6050–6059.[CrossRef][Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				M. Mizobuchi, D. Towler, and E. Slatopolsky Vascular Calcification: The Killer of Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1453 - 1464. [Abstract] [Full Text] [PDF]

				M. T. Mizwicki and A. W. Norman The Vitamin D Sterol-Vitamin D Receptor Ensemble Model Offers Unique Insights into Both Genomic and Rapid-Response Signaling Sci. Signal., June 16, 2009; 2(75): re4 - re4. [Abstract] [Full Text] [PDF]

				E. R. Levin Rapid signaling by steroid receptors Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2008; 295(5): R1425 - R1430. [Abstract] [Full Text] [PDF]

				N. Thongon, L.-i. Nakkrasae, J. Thongbunchoo, N. Krishnamra, and N. Charoenphandhu Prolactin stimulates transepithelial calcium transport and modulates paracellular permselectivity in Caco-2 monolayer: mediation by PKC and ROCK pathways Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1158 - C1168. [Abstract] [Full Text] [PDF]

				S. R. Hammes and E. R. Levin Extranuclear Steroid Receptors: Nature and Actions Endocr. Rev., December 1, 2007; 28(7): 726 - 741. [Abstract] [Full Text] [PDF]

				C. Guilluy, M. Rolli-Derkinderen, P.-L. Tharaux, G. Melino, P. Pacaud, and G. Loirand Transglutaminase-dependent RhoA Activation and Depletion by Serotonin in Vascular Smooth Muscle Cells J. Biol. Chem., February 2, 2007; 282(5): 2918 - 2928. [Abstract] [Full Text] [PDF]

				A. W. Norman Vitamin D Receptor: New Assignments for an Already Busy Receptor Endocrinology, December 1, 2006; 147(12): 5542 - 5548. [Abstract] [Full Text] [PDF]

				Y. Hiroi, H.-H. Kim, H. Ying, F. Furuya, Z. Huang, T. Simoncini, K. Noma, K. Ueki, N.-H. Nguyen, T. S. Scanlan, et al. Rapid nongenomic actions of thyroid hormone PNAS, September 19, 2006; 103(38): 14104 - 14109. [Abstract] [Full Text] [PDF]

				Y. Ma, W.-D. Yu, R.-X. Kong, D. L. Trump, and C. S. Johnson Role of Nongenomic Activation of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase 1/2 Pathways in 1,25D3-Mediated Apoptosis in Squamous Cell Carcinoma Cells Cancer Res., August 15, 2006; 66(16): 8131 - 8138. [Abstract] [Full Text] [PDF]

				S. Briese, S. Wiesner, J. C. Will, A. Lembcke, B. Opgen-Rhein, R. Nissel, K.-D. Wernecke, J. Andreae, D. Haffner, and U. Querfeld Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease--impact of calcium and vitamin D therapy Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1906 - 1914. [Abstract] [Full Text] [PDF]

				C. P. Schmitt, T. Odenwald, and E. Ritz Calcium, Calcium Regulatory Hormones, and Calcimimetics: Impact on Cardiovascular Mortality J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S78 - S80. [Abstract] [Full Text] [PDF]

				J. J. Bergh, Y. Shao, E. Puente, R. L. Duncan, and M. C. Farach-Carson Osteoblast Ca2+ permeability and voltage-sensitive Ca2+ channel expression is temporally regulated by 1,25-dihydroxyvitamin D3 Am J Physiol Cell Physiol, March 1, 2006; 290(3): C822 - C831. [Abstract] [Full Text] [PDF]

				C. M. Bula, J. Huhtakangas, C. Olivera, J. E. Bishop, A. W. Norman, and H. L. Henry Presence of a Truncated Form of the Vitamin D Receptor (VDR) in a Strain of VDR-Knockout Mice Endocrinology, December 1, 2005; 146(12): 5581 - 5586. [Abstract] [Full Text] [PDF]

				M. M. Bachschmid and B. van der Loo A New "Sunshine" in the Vasculature? Circulation, April 5, 2005; 111(13): 1571 - 1573. [Full Text] [PDF]

				D. Somjen, Y. Weisman, F. Kohen, B. Gayer, R. Limor, O. Sharon, N. Jaccard, E. Knoll, and N. Stern 25-Hydroxyvitamin D3-1{alpha}-Hydroxylase Is Expressed in Human Vascular Smooth Muscle Cells and Is Upregulated by Parathyroid Hormone and Estrogenic Compounds Circulation, April 5, 2005; 111(13): 1666 - 1671. [Abstract] [Full Text] [PDF]

				P.E. Norman and J.T. Powell Vitamin D, Shedding Light on the Development of Disease in Peripheral Arteries Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 39 - 46. [Abstract] [Full Text] [PDF]

				J. A. Huhtakangas, C. J. Olivera, J. E. Bishop, L. P. Zanello, and A. W. Norman The Vitamin D Receptor Is Present in Caveolae-Enriched Plasma Membranes and Binds 1{alpha},25(OH)2-Vitamin D3 in Vivo and in Vitro Mol. Endocrinol., November 1, 2004; 18(11): 2660 - 2671. [Abstract] [Full Text] [PDF]

				M. T. Mizwicki, D. Keidel, C. M. Bula, J. E. Bishop, L. P. Zanello, J.-M. Wurtz, D. Moras, and A. W. Norman Identification of an alternative ligand-binding pocket in the nuclear vitamin D receptor and its functional importance in 1{alpha},25(OH)2-vitamin D3 signaling PNAS, August 31, 2004; 101(35): 12876 - 12881. [Abstract] [Full Text] [PDF]

				L. A. Stevens, O. Djurdjev, S. Cardew, E. C. Cameron, and A. Levin Calcium, Phosphate, and Parathyroid Hormone Levels in Combination and as a Function of Dialysis Duration Predict Mortality: Evidence for the Complexity of the Association between Mineral Metabolism and Outcomes J. Am. Soc. Nephrol., March 1, 2004; 15(3): 770 - 779. [Abstract] [Full Text] [PDF]

				H. Maekawa, Y. Oike, S. Kanda, Y. Ito, Y. Yamada, H. Kurihara, R. Nagai, and T. Suda Ephrin-B2 Induces Migration of Endothelial Cells Through the Phosphatidylinositol-3 Kinase Pathway and Promotes Angiogenesis in Adult Vasculature Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 2008 - 2014. [Abstract] [Full Text] [PDF]

				M. Sata and R. Nagai Phosphatidylinositol 3-Kinase: A Key Regulator of Vascular Tone? Circ. Res., August 23, 2002; 91(4): 273 - 275. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 91/1/17    most recent 01.RES.0000025269.60668.0Fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rebsamen, M. C. Articles by Liao, J. K. Search for Related Content PubMed PubMed Citation Articles by Rebsamen, M. C. Articles by Liao, J. K. Related Collections Pathophysiology Cell signalling/signal transduction Smooth muscle proliferation and differentiation Mechanism of atherosclerosis/growth factors